AbbVie hepatitis C drugs show high cure rate ahead of filing
This article was originally published in Scrip
Executive Summary
AbbVie said its all-oral hepatitis C regimen cleared the virus in most patients in a late-stage study that will be used as part of the company’s approval application next year.